Attention Deficit Hyperactivity Disorder (ADHD) Market to grow with a CAGR of 4.10%

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Attention Deficit Hyperactivity Disorder (ADHD) Market

According to TechSci Research report, “Global Attention Deficit Hyperactivity Disorder (ADHD) Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Attention Deficit Hyperactivity Disorder (ADHD) Market has valued at USD 15.30 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 4.10% through 2028. This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market.

Mental health plays a significant role in driving the demand for services and treatments within the attention deficit hyperactivity disorder (ADHD) market. Individuals with ADHD often experience co-existing mental health conditions such as anxiety, depression, bipolar disorder, and oppositional defiant disorder. These conditions can exacerbate ADHD symptoms and significantly impact an individual's mental well-being. As a result, there is a heightened demand for comprehensive evaluation and treatment of both ADHD and co-occurring mental health conditions. ADHD can affect emotional regulation, leading to mood swings, frustration, and low self-esteem. Individuals with ADHD may struggle with emotional self-regulation, making it essential to address their emotional well-being through therapy and support. Early intervention for ADHD, including diagnosis and treatment, is critical for improving mental health outcomes. Identifying and addressing ADHD in childhood can prevent or mitigate the development of mental health issues that may arise because of untreated or undertreated ADHD. Broader societal trends emphasizing the importance of mental health and well-being have raised awareness about conditions like ADHD. As mental health gains prominence, there is a growing recognition of the need for comprehensive ADHD care.

Attention Deficit Hyperactivity Disorder, is the most prevalent neurodevelopmental disorder, predominantly observed in children. It typically surfaces in childhood and frequently persists into adulthood. The primary symptoms of ADHD include children frequently engaging in daydreaming, experiencing forgetfulness, or misplacing items, struggling to resist impulses, encountering difficulties in sharing and taking turns, facing challenges in social interactions, exhibiting excessive activity, and experiencing difficulties in maintaining attention. The treatment for ADHD involves the use of both stimulant and non-stimulant medications.

In March 2021, KemPharm, Inc., a specialty pharmaceutical company focused on developing proprietary prodrugs, has received approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for AZSTARYS, previously known as KP415. This once-daily product is designed for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged six years and older. AZSTARYS combines serdexmethylphenidate (SDX), KemPharm's prodrug of d-methylphenidate (d-MPH), with immediate-release d-MPH. The commercialization of AZSTARYS will be led by Corium, Inc. (Corium), a company under the portfolio of Gurnet Point Capital (GPC), as per the definitive collaboration and license agreement (the "License Agreement") between KemPharm and an affiliate of GPC.

The cost of treatment is a significant challenge in the Global Attention Deficit Hyperactivity Disorder (ADHD) market. The cost of ADHD medications, both stimulant and non-stimulant, can be a substantial financial burden for individuals and their families. Some medications may not be covered by insurance, leading to out-of-pocket expenses. ADHD is a chronic condition that often requires long-term treatment. This means that individuals may need to continue taking medications and attending therapy sessions over an extended period, resulting in ongoing costs. While behavioral therapies are an important component of ADHD treatment, they can also be costly, especially if they are not fully covered by health insurance plans. Some individuals with ADHD may require specialized services, such as educational support, tutoring, or occupational therapy. These services can add to the overall cost of managing the condition. The process of diagnosing ADHD often involves clinical assessments and evaluations, which can incur expenses. Additionally, obtaining a formal diagnosis may be a prerequisite for accessing treatment and support services.

Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " Global Attention Deficit Hyperactivity Disorder (ADHD) Market”

Global Attention Deficit Hyperactivity Disorder (ADHD) Market is segmented based on Drug Type, Distribution Channel,  region, and by company

Based on the Drug Type, Global Attention Deficit Hyperactivity Disorder (ADHD) Market is segmented into Stimulant, Non-stimulant. Non-stimulant drugs are a class of medications used in the treatment of attention deficit hyperactivity disorder (ADHD). Unlike stimulant medications, which are commonly prescribed for ADHD, non-stimulant drugs have different mechanisms of action and can be used as an alternative when stimulants are not well-tolerated, are ineffective, or are not suitable for a particular individual. Non-stimulant drugs used for ADHD primarily target different neurotransmitters or receptors in the brain compared to stimulant medications. They aim to modulate brain chemistry to improve attention, impulse control, and other ADHD symptoms. There are several non-stimulant medications approved for the treatment of ADHD. Two common non-stimulant drugs used for ADHD are atomoxetine (Strattera) and guanfacine (Intuniv). Additionally, other medications, such as bupropion (Wellbutrin), may be used off-label for ADHD treatment. Non-stimulant drugs are considered an option when stimulant medications are not appropriate due to factors such as a history of substance abuse, severe side effects, or ineffectiveness. They do not carry the risk of addiction or misuse associated with stimulants.

Based on Region, North America held the largest share in the Global Attention Deficit Hyperactivity Disorder (ADHD) Market. North America is a hub for medical research and innovation, with ongoing studies and clinical trials related to ADHD. This continuous research leads to the development of new treatments and therapies. The presence of comprehensive health insurance coverage in North America often ensures that individuals with ADHD have access to medications and therapeutic interventions without significant financial barriers. Legislation such as the Individuals with Disabilities Education Act (IDEA) in the United States ensures that students with ADHD receive appropriate educational services and accommodations, which can drive awareness and treatment. There are numerous patient advocacy groups and organizations in North America dedicated to ADHD, providing resources, support, and information to individuals and families affected by the condition. Cultural factors, including a willingness to seek medical help for mental health conditions and a culture of early intervention, can contribute to higher ADHD diagnosis rates.

Some of the major companies operating in the Global Attention Deficit Hyperactivity Disorder (ADHD) Market include:

• Supernus Pharmaceuticals, Inc.
• Pfizer Inc
• Novartis AG
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Johnson & Johnson
• Hisamitsu Pharmaceutical Co., Inc.
• Chongqing Fujin Biology Medical Company
• Purdue Pharma LP
• Mallinckrodt Pharmaceuticals

Download Free Sample Report

Customers can also request 10% free customization on this report

“Certain areas, particularly in North America, are projected to exert significant demand for the treatment of attention deficit hyperactivity disorder (ADHD). The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global Attention Deficit Hyperactivity Disorder (ADHD) Market in the forecast period," said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

Attention Deficit Hyperactivity Disorder (ADHD) Market by Drug Type (Stimulant, Non-stimulant), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, online Pharmacies, By Region, By Competition Forecast & Opportunities, 2018-2028F has evaluated the future growth potential of Global Attention Deficit Hyperactivity Disorder (ADHD) Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Attention Deficit Hyperactivity Disorder (ADHD) Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com